Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
Authors
Keywords
Bone turnover, Denosumab, Osteoporosis, Post-denosumab, Vertebral fractures
Journal
OSTEOPOROSIS INTERNATIONAL
Volume 29, Issue 1, Pages 41-47
Publisher
Springer Nature
Online
2017-10-04
DOI
10.1007/s00198-017-4242-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment
- (2017) Athanasios D Anastasilakis et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
- (2017) Athanasios D Anastasilakis et al. JOURNAL OF BONE AND MINERAL RESEARCH
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
- (2017) Henry G Bone et al. Lancet Diabetes & Endocrinology
- Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
- (2016) A. Lipton et al. EUROPEAN JOURNAL OF CANCER
- Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report
- (2016) Olivier Lamy et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Cancel the denosumab holiday
- (2016) M. R. McClung OSTEOPOROSIS INTERNATIONAL
- A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial
- (2015) Bente L. Langdahl et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports
- (2015) B. Aubry-Rozier et al. OSTEOPOROSIS INTERNATIONAL
- Multiple clinical vertebral fractures following denosumab discontinuation
- (2015) A. D. Anastasilakis et al. OSTEOPOROSIS INTERNATIONAL
- Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics
- (2015) A. W. Popp et al. OSTEOPOROSIS INTERNATIONAL
- Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
- (2012) Jacques P Brown et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of denosumab on fracture and bone mineral density by level of kidney function
- (2011) Sophie A Jamal et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
- (2011) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
- (2011) N. Freemantle et al. OSTEOPOROSIS INTERNATIONAL
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now